Our Case 1 falls into this pathogenetic category and represents a novel observation in this type of uterine sarcomas, indicating that mutant ERBB3 concurrent with ERBB2 amplification represents a novel mechanism driving oncogenesis in tumors lacking the V777L ERBB2 mutation. Here, ERBB3 is linked to uterine corpus sarcoma.